Cytiva, a Danaher unit specializing in biopharma tools and services, announced completion and growth of $1.6 billion in global expansion initiatives across the U.S., Europe, and Asia. These projects target increased regional production capacities to serve advanced therapeutic developers faster and with improved sustainability metrics. Leadership emphasized customer demand for in-region manufacturing to reduce supply chain vulnerabilities and carbon footprints. Cytiva’s investments support its long-term growth strategy and reflect rising market needs for localized advanced biologics manufacturing infrastructure.